Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy.
Sota KuriharaAkihiro IshikawaShin KanekoPublished in: Inflammation and regeneration (2024)
In recent years, immunotherapy has become a standard cancer therapy, joining surgery, chemotherapy, and radiation therapy. This therapeutic approach involves the use of patient-derived antigen-specific T cells or genetically modified T cells engineered with chimeric antigen receptors (CAR) or T cell receptors (TCR) that specifically target cancer antigens. However, T cells require ex vivo stimulation for proliferation when used in therapy, and the resulting "exhaustion," which is characterized by a diminished proliferation capacity and anti-tumor activity, poses a significant challenge. As a solution, we reported "rejuvenated" CD8 + T cells that possess high proliferation capacity from induced pluripotent stem cells (iPSCs) in 2013. This review discusses the status and future developments in immunotherapy using iPSC-derived T cells, drawing insights from our research to overcome the exhaustion associated with antigen-specific T cell therapy.
Keyphrases
- cell therapy
- induced pluripotent stem cells
- genome editing
- crispr cas
- radiation therapy
- stem cells
- signaling pathway
- cancer therapy
- mesenchymal stem cells
- minimally invasive
- locally advanced
- papillary thyroid
- dna repair
- squamous cell carcinoma
- dendritic cells
- current status
- dna damage
- coronary artery disease
- atrial fibrillation
- acute coronary syndrome
- squamous cell
- nk cells
- lymph node metastasis
- rectal cancer
- solid state